Author: Alyssa Rose

Insurers face uncertainty as 2024 concludes, grappling with market volatility and regulatory challenges that threaten stability and profitability.

Physicians warn that prior authorization processes delay essential medical care, impacting patient health and access to necessary treatments.

Biotech investors voice worries over potential NIH research funding cuts, fearing impacts on innovation and industry growth.

FDA reinstates some previously dismissed device staff, aiming to enhance oversight and improve regulatory processes for medical devices.

Veradigm announces a reshuffle of its Board of Directors, aiming to enhance governance and drive strategic growth in the healthcare technology sector.